Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection

This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3) hepatitis C virus (HCV) infections.

Inclusion Criteria:

• Body weight ≥ 88 lbs and ≤ 275 lbs
• Documented chronic Hepatitis C (CHC) GT2 or GT3 infection
• No known cirrhosis
• Agrees to use two acceptable methods of birth control during study and through 6 months after last dose of study drug
• Chest X-ray within the last 6 months
• Eye exam within the last 6 months

Exclusion Criteria:

• Known to be human immunodeficiency virus (HIV) positive or co-infected with active hepatitis B virus (positive for Hepatitis B surface antigen)
• Prior approved or investigational treatment for hepatitis C
• Evidence of hepatocellular carcinoma
• Diabetic and/or high blood pressure with clinically significant eye exam findings
• Pre-existing psychiatric condition
• Clinical diagnosis of abuse of certain substances within specified timeframes
• Known medical condition that could interfere with participation
• Active or suspected cancer within the last 5 years
• Female who is pregnant, breastfeeding, or expecting to conceive or donate eggs
• Male who is planning to impregnate partner or donate sperm
• Male with a pregnant female partner
• Chronic hepatitis not caused by HCV